Review of cardiovascular effects of ADHD medications

Charles J. Levin, David Goodman, Lenard A. Adler

Research output: Contribution to journalArticle

Abstract

The prevalence of attention-deficit/hyperactivity disorder (ADHD) among adults is approximately 4.4%, and more than 1.5 million Americans are prescribed stimulants for the treatment of ADHD. Stimulants (such as methylphenidate and amphetamine compounds), along with the nonstimulant atomoxetine, are widely prescribed for ADHD, and more Americans are continuing to use these medications throughout their adult lives. Given the action of these drugs on the cardiovascular system, health care professionals have asked whether chronic use of these substances substantively increase the risk for cardiovascular disease (CVD). A comprehensive body of research suggests that this may not be the case. All adult patients should be monitored for changes in blood pressure and pulse during treatment with ADHD medications; furthermore, people at risk for CVD or with existing CVD should be evaluated at baseline in conjunction with appropriate medical personnel, and ongoing treatment should be collaborative with such medical colleagues.

Original languageEnglish (US)
Pages (from-to)323-327
Number of pages5
JournalPsychiatric Annals
Volume48
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Attention Deficit Disorder with Hyperactivity
Cardiovascular Diseases
Methylphenidate
Amphetamine
Cardiovascular System
Pulse
Therapeutics
Blood Pressure
Delivery of Health Care
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Review of cardiovascular effects of ADHD medications. / Levin, Charles J.; Goodman, David; Adler, Lenard A.

In: Psychiatric Annals, Vol. 48, No. 7, 01.07.2018, p. 323-327.

Research output: Contribution to journalArticle

Levin, Charles J. ; Goodman, David ; Adler, Lenard A. / Review of cardiovascular effects of ADHD medications. In: Psychiatric Annals. 2018 ; Vol. 48, No. 7. pp. 323-327.
@article{28753d1d75b74c1b9b7acb69f4bb2b67,
title = "Review of cardiovascular effects of ADHD medications",
abstract = "The prevalence of attention-deficit/hyperactivity disorder (ADHD) among adults is approximately 4.4{\%}, and more than 1.5 million Americans are prescribed stimulants for the treatment of ADHD. Stimulants (such as methylphenidate and amphetamine compounds), along with the nonstimulant atomoxetine, are widely prescribed for ADHD, and more Americans are continuing to use these medications throughout their adult lives. Given the action of these drugs on the cardiovascular system, health care professionals have asked whether chronic use of these substances substantively increase the risk for cardiovascular disease (CVD). A comprehensive body of research suggests that this may not be the case. All adult patients should be monitored for changes in blood pressure and pulse during treatment with ADHD medications; furthermore, people at risk for CVD or with existing CVD should be evaluated at baseline in conjunction with appropriate medical personnel, and ongoing treatment should be collaborative with such medical colleagues.",
author = "Levin, {Charles J.} and David Goodman and Adler, {Lenard A.}",
year = "2018",
month = "7",
day = "1",
doi = "10.3928/00485713-20180612-01",
language = "English (US)",
volume = "48",
pages = "323--327",
journal = "Psychiatric Annals",
issn = "0048-5713",
publisher = "Slack Incorporated",
number = "7",

}

TY - JOUR

T1 - Review of cardiovascular effects of ADHD medications

AU - Levin, Charles J.

AU - Goodman, David

AU - Adler, Lenard A.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The prevalence of attention-deficit/hyperactivity disorder (ADHD) among adults is approximately 4.4%, and more than 1.5 million Americans are prescribed stimulants for the treatment of ADHD. Stimulants (such as methylphenidate and amphetamine compounds), along with the nonstimulant atomoxetine, are widely prescribed for ADHD, and more Americans are continuing to use these medications throughout their adult lives. Given the action of these drugs on the cardiovascular system, health care professionals have asked whether chronic use of these substances substantively increase the risk for cardiovascular disease (CVD). A comprehensive body of research suggests that this may not be the case. All adult patients should be monitored for changes in blood pressure and pulse during treatment with ADHD medications; furthermore, people at risk for CVD or with existing CVD should be evaluated at baseline in conjunction with appropriate medical personnel, and ongoing treatment should be collaborative with such medical colleagues.

AB - The prevalence of attention-deficit/hyperactivity disorder (ADHD) among adults is approximately 4.4%, and more than 1.5 million Americans are prescribed stimulants for the treatment of ADHD. Stimulants (such as methylphenidate and amphetamine compounds), along with the nonstimulant atomoxetine, are widely prescribed for ADHD, and more Americans are continuing to use these medications throughout their adult lives. Given the action of these drugs on the cardiovascular system, health care professionals have asked whether chronic use of these substances substantively increase the risk for cardiovascular disease (CVD). A comprehensive body of research suggests that this may not be the case. All adult patients should be monitored for changes in blood pressure and pulse during treatment with ADHD medications; furthermore, people at risk for CVD or with existing CVD should be evaluated at baseline in conjunction with appropriate medical personnel, and ongoing treatment should be collaborative with such medical colleagues.

UR - http://www.scopus.com/inward/record.url?scp=85050406953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050406953&partnerID=8YFLogxK

U2 - 10.3928/00485713-20180612-01

DO - 10.3928/00485713-20180612-01

M3 - Article

VL - 48

SP - 323

EP - 327

JO - Psychiatric Annals

JF - Psychiatric Annals

SN - 0048-5713

IS - 7

ER -